Conference Presentation, Panel, Fireside Chat
The Remarkable Potential of Precision Medicine
- Precision medicine is projected to evolve into a more personalized, preventive, and cost-effective standard by integrating massive data networks across epidemiology, environment, microbiome, and metabolome layers.
- Genome sequencing is expected to become a 10 to 15-minute process costing a few hundred dollars, a significant reduction from current figures of several hours and approximately $1,000.
- The current drug development pipeline, which takes roughly 15 years, costs between $2 and $10 billion, and fails 99.9 percent of the time, is targeted for improvement through the National Center for Advancing Translational Research (NCATS) and cross-disease discovery approaches that can shorten timelines to under a year.
- Based on a current rate of three untreatable diseases becoming treatable annually, it is estimated that 2,000 years would be required to address every human disease without accelerated translational methods.
- Major financial commitments are underway, including China's pledge of 1.9 trillion in bioscience investments and Singapore's allocation of nearly 40 percent of a budget equivalent to the NIH's despite a population less than one-fiftieth the size of the United States.
- Healthcare applications are projected to see download numbers rise from 44 million in 2012 to 142 million by 2016.
- Mental disorders, particularly depression, are identified as a primary driver of healthcare costs due to absenteeism and presenteeism, expected to remain higher than costs associated with cancer or diabetes.
- California is positioned to become the world headquarters for precision medicine through consolidation of university and for-profit technology efforts, leveraging its eight most profitable technology companies and hosting six of the top 12 biotech metropolitan areas, with San Diego ranked first.
- Universities are expected to vertically integrate discovery, engineering, big data, prevention, and therapy, moving from "bench side to bed side" through collaborations such as the partnership between UC San Diego and the Craig Venter Institute, which involves hundreds of millions in private investment on property leased for one dollar annually.
- Disease classification is expected to shift from symptoms to underlying mechanistic causes by 10 to 15 years, utilizing diagnosis based on mutations or gene changes to treat previously unrelated conditions together.
- Toxicology and drug testing are anticipated to transition from animal models to human tissues and high-tech organoids, including individualized tissue chips, to predict efficacy and avoid side effects before clinical administration.
- Big data integration is forecast to become a reality within 15 to 20 years, enabling researchers to determine molecular interactions without wet experiments by searching databases of 8 million to 12 million patients across UC campuses.
- Life expectancy for cystic fibrosis patients is expected to increase from approximately 18 years to 37 years, driven by the reactivation of clinical trials for existing drugs, such as a Pfizer initiative involving $59 million and revenue-sharing agreements.
- Stem cell efforts and partnerships with digital, computer, and aerospace industries are expected to serve as platform technologies transforming health through tool creation, algorithm development, and new educational opportunities.
- Collaboration in San Diego is expected to strengthen through shared resources, libraries, and PhD students, aiming to create a seamless and frictionless tech transfer process among institutions like UCSD, Salk, and Sanford Burnham.
- Mental disorders represent a major area for precision medicine impact, with the potential to generate a new global industry class if specific mutations or drug response patterns are successfully identified.
- Precision medicine promises to reduce overall healthcare costs while increasing both the length and quality of life for patients by treating specific individual mutations rather than assuming a single treatment applies to all.